IBIO

distress 4/10 · elevated risk

$1.35-2%today-56% from 52w high

ibioinc.com20 employeesFounded 2008San Diego, CABiotechnology

Lead: obesity · est. market ~$15B (approx, global)

Revenue

pre-revenue

Liquidity

$48M

Runway

3.1 yrs

Shares 1y

+153%

Price & events

-43.3% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.8%

+0.4%

-17.9%

-25.1%

-39.8%

+78.3%

-41.6%

-99.8%

All

Overview

Market Cap: $67.31M
Volume: 40.49K
52 Week Range: $0.57 – $3.07
Total Shares: 49.68M
Float Shares: 45.47M
Short %: 9.50%
% Held by Insiders: 1.71%
% Held by Institutions: 48.65%
RVOL: 0.04x
Beta: 1.27

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 13

2H '26regulatory submissionFiled (NDA/BLA)undisclosed · Additional IND filingSEC 8-K
end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)IBIO-610 · IND/IND equivalent filing for IBIO-610SEC 8-K
second half of 2026regulatory submissionFiled (NDA/BLA)Additional IND submission for another programSEC 8-K
second half of 2026trial initiationsecondaryPhase 1IBIO-600 · Initiate Phase 1 trial for IBIO-600SEC 8-K
2H '26trial initiationsecondaryPhase 1anti-Myostatin · Phase 1 trial for long-acting anti-Myostatin initiatedSEC 8-K
Thursday, October 1, 2026, 12:45-13:45 ETConfirmed 100%conferencedata presentationsecondaryIBIO-610 · Presentation of preclinical data at EASD Annual MeetingSEC 8-K
second quarter of 2026trial initiationsecondaryPhase 1IBIO-600 · First participants expected to be dosed in Phase 1 SAD trial of IBIO-600 in Australia.SEC 8-K
Q1 2026regulatory submissionFiled (NDA/BLA)IBIO-600 · Regulatory submission for IBIO-600SEC 8-K
Q4 '25/Q1'26regulatory submissionFiled (NDA/BLA)anti-Myostatin · IND filing for long-acting anti-Myostatin programSEC 8-K
Q4 2025 / Q1 2026regulatory submissionFiled (NDA/BLA)IBIO-600 · IND submission for long-acting anti-myostatin antibodySEC 8-K
November 4-7, 2025conferencedata presentationsecondaryIBIO-610 · Oral presentation at ObesityWeek 2025SEC 8-K
2025-04-21partnershipiBio enters exclusive license agreement with AstralBio for an antibody targeting activin E, including upfront fee and milestone payments up to $28M.SEC 8-K
2024-12-31partnershipIBIO-600 · Exclusive worldwide in-license of anti-myostatin antibody from AstralBio; upfront stock payment and up to $28M milestones.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 49,678,561 · 5 offerings/1y · 1 PIPEs

2026-04-29424B3offering
2026-03-06EFFECTshelf_effective
2026-03-06424B5offering
2026-02-278-Kmaterial_agreement
2026-02-27S-3shelf_registration
2026-02-09424B3offering
2026-02-09EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $5 (+299% upside) · 8 analysts

2026-07-02Chardan CapitalBuy
2026-06-08Raymond JamesOutperform
2026-04-09Chardan CapitalBuy
2026-03-18Chardan CapitalBuy
2026-03-03Jones TradingBuy
2026-02-12Chardan CapitalBuy

Competitors — obesity

LLYELI LILLY & Co$1094.4B · D3
AMGNAMGEN INC$195.4B · D3
GPCRStructure Therapeutics Inc.$11.2B · D4
RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
MBXMBX Biosciences, Inc.$2.8B · D2
WVEWave Life Sciences Ltd.$1.1B · D1
CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
GUTSFRACTYL HEALTH, INC.$123M · D9
MTVAMetaVia Inc.$8M · D7
NONOFNOVO NORDISK A S— · D2

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.